| Name | Title | Contact Details |
|---|
Guadalupe Regional Medical Center is committed to providing sophisticated facilities and services with an emphasis on personalized care.
Envision Healthcare is on the front lines of change. Through our primary business units – Envision Physician Services, Evolution Health and AMSURG – our clinician-led organization is changing the face of healthcare by delivering high-quality care that elevates the patient experience. Envision Healthcare is pioneering solutions to the toughest challenges in healthcare. We serve as a partner to help navigate the constantly evolving landscape of healthcare delivery, and we are vigilant in working with health systems and hospitals to identify opportunities to better serve our communities. Our physicians, advanced practice providers and support teams are responsible for more than 30 million annual patient encounters across the U.S. Learn more about how we care for patients here.MISSION Our mission is to improve the patient experience and public health while reducing the cost of available healthcare per capita. As the largest provider of physician services to hospital and health systems through Envision Physician Services, we are committed to supporting our hospital and health system partners in delivering local, high-quality care. COMMUNITIES Our employees are committed to supporting the communities we serve by providing charitable donations. Our time is dedicated to helping our communities remain safe, active, healthy and productive by getting involved and giving back.
Redwood Green Corp. delivers high-quality, safe, sustainable, innovative and accessible cannabis-derived products that support individual well-being. Safety and high quality is a critical commitment from Redwood Green, both for our own brands as well as the partners with whom we do business. The drive behind what we do is rooted in improving well-being and quality of life for a wide range of audiences, ensuring we grow and improve upon what is currently available for consumers in the cannabinoids market. The company is publicly traded and listed on the OTC as RDGC.
We aim to make personalized brain health a reality.For everyone. Linus Health integrates the latest in cutting-edge neuroscience and AI technology with everyday digital tools to give individuals and their care professionals up-to-the-minute brain healt...
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.